Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390

Published:2023-04-26 Issue:5 Volume:46 Page:e120-e120
ISSN:0149-5992
Container-title:Diabetes Care
language:en
Short-container-title:

Author:

Smits Mark M.¹²³^ORCID,van Raalte Daniël H.¹²

Affiliation:

1. 1Department of Endocrinology and Metabolism and Diabetes Center, Amsterdam UMC location Vrije Universiteit, Amsterdam, the Netherlands

2. 2Amsterdam Cardiovascular Sciences, Diabetes & Metabolism, Amsterdam, the Netherlands

3. 3Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

Publisher

American Diabetes Association

Subject

Advanced and Specialized Nursing,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://diabetesjournals.org/care/article-pdf/46/5/e120/702189/dc230134.pdf

Reference5 articles.

1. GLP-1 receptor agonists and the risk of thyroid cancer;Bezin;Diabetes Care,2023

2. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation;Bjerre Knudsen;Endocrinology,2010

3. The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020;Pizzato;Lancet Diabetes Endocrinol,2022

4. Case–non-case studies: principle, methods, bias and interpretation;Faillie;Therapies,2019

5. Weighing risks and benefits of liraglutide—the FDA’s review of a new antidiabetic therapy;Parks;N Engl J Med,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity—Reply;JAMA;2024-05-21

2. Disadvantages of the obesity blockbuster illuminated;Die Diabetologie;2023-10-11

3. Response to Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390;Diabetes Care;2023-04-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3